STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early

STAT PlusBiotech Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early Pancreatic cancer therapy data and deescalation trials highlighted at ESMO meeting in Madrid Manage alerts for this article Save this story for later Share this article By Andrew Joseph and Adam FeuersteinOct. 23, 2026 Andrew Joseph[email protected]Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology.

He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. You’re reading our ESMO in 30 Seconds newsletter.

Sign up here to get updates from the major European cancer conference in your inbox. Hello from Madrid, where this year’s European Society for Medical Oncology conference got off to an unexpected start with the leak of the meeting’s most anticipated data. See below for a rundown of what’s happened, and stay with us the next few days as we cover the reaction to that study and a whole lot more.

We’re at [email protected] and [email protected] for any thoughts, questions, or opinions on what makes a good vermouth. Advertisement The Moderna-Merck melanoma cancer vaccine data arrived early As reporters, nothing juices your adrenaline, or spikes your frustration, more than a major embargo violation of the most highly anticipated data presentation at ESMO. All carefully laid plans went right out the window on the eve of the conference.

We were NOT the guilty party. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%!

2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In Cancer, ESMO, research, STAT+ Submit a correction requestReprints Andrew Joseph Europe Correspondent Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Biotech October 23, 2026 STAT Plus: Patient dies in Bristol Myers Squibb autoimmune CAR-T trial Biotech October 23, 2026 STAT Plus: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials Advertisement The Readout October 23, 2026 STAT Plus: Tango builds on Revolution Medicines’ pancreatic cancer success Biotech October 23, 2026 STAT Plus: Treasury proposes major restrictions to U.S. investment in Chinese biotech sector Health tech October 23, 2026 STAT Plus: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion Subscriber Picks